PAREXEL International Corporation (NASDAQ: PRXL), a leading global bio/pharmaceutical services organization, today announced that Todd A. Joron, MBA, has been appointed to the role of Corporate Vice President and General Manager of Perceptive Informatics, Inc., a wholly-owned subsidiary of PAREXEL that provides technology products and services.
- Chairman and CEO Josef von Rickenbach to ring opening bell at The NASDAQ Stock Market -
Leads PAREXEL businesses focused on healthcare product commercialization strategies and programs
- Achieves record backlog of $782 million -
PAREXEL International Corporation (Nasdaq: PRXL) will release First Quarter Fiscal Year 2006 financial results on Wednesday, October 19, 2005 after the close of the stock market.
PAREXEL International Corporation (Nasdaq: PRXL) today announced that on August 22, 2005 it acquired all of the shares held by minority stockholders of Perceptive Informatics, Inc., its information technology subsidiary, and now owns all of the outstanding common stock of Perceptive.
PAREXEL International Corporation (Nasdaq: PRXL) today announced its financial results for the fourth quarter and fiscal year ended June 30, 2005.
PAREXEL International Corporation (Nasdaq: PRXL) today announced the acquisition of QdotPharma, a leading Phase I and IIa Proof of Concept clinical pharmacology business located in George, South Africa.
PAREXEL International Corporation (Nasdaq: PRXL) will release Fourth Quarter and Fiscal Year 2005 financial results on Monday, August 1, 2005 after the close of the stock market.
PAREXEL International Corporation (Nasdaq: PRXL) today announced its forward-looking financial expectations for the fourth quarter of Fiscal 2005 (ending June 30, 2005), Fiscal 2005 in its entirety, and Fiscal 2006.
PAREXEL International Corporation (Nasdaq: PRXL) will issue earnings guidance on Thursday morning, June 30, 2005 before the opening of the stock market.
According to PAREXEL's Pharmaceutical R&D Statistical Sourcebook 2005/2006, the bio/pharmaceutical industry’s U.S.-based clinical research activity for drugs rose 6.1% in 2004.
Originates from Own Experts
The Company is educating the industry about its comprehensive toolkit of services and technologies to assist with the development and commercialization of bio/pharmaceutical products
Expertise that makes the Difference™
PAREXEL International Corporation (Nasdaq: PRXL) today announced that Carl A. Spalding, PAREXEL’s Chief Operating Officer, has decided to retire effective June 30, 2005.
PAREXEL International Corporation (Nasdaq: PRXL) today announced that it will record a charge in the fourth quarter of Fiscal 2005 (ending June 30, 2005) in connection with restructuring activities it is undertaking.
PAREXEL International Corporation (Nasdaq: PRXL) today announced its financial results for the third quarter and nine months ended March 31, 2005.
PAREXEL International Corporation (Nasdaq: PRXL) will release Third Quarter Fiscal Year 2005 financial results on Thursday, April 21, 2005 after the close of the stock market.
PAREXEL International Corporation (Nasdaq: PRXL) announced today it will be presenting at the UBS Global Healthcare Services Conference at The Plaza Hotel in New York City.
Global ECG solutions offered for comprehensive clinical trials
- Diluted earnings per share increase 21% - Backlog exceeds $720 million
